(Q36616386)

English

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

scientific article published on March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

J P Delord

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J Y Pierga

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

V Dieras

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

F Bertheault-Cvitkovic

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

F L Turpin

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

F Lokiec

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

I Lochon

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

E Chatelut

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

P Canal

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

R Guimbaud

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

D Mery-Mignard

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

X Cornen

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Z Mouri

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

R Bugat

14

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

92

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

820-826

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602354

0 references

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Clinical pharmacokinetics of capecitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

30 September 2017

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

20 September 2018

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

20 September 2018

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

20 September 2018

Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361914

20 September 2018

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacology of irinotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602354

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36616386&oldid=2143361741"